Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Stifel analyst Jonathan Block reinstates Insulet (NASDAQ:PODD) with a Buy and announces $370 price target.
Insulet (NASDAQ: PODD) has outperformed the market over the past 15 years by 10.02% on an annualized basis producing an average...
6 analysts have shared their evaluations of Insulet (NASDAQ: PODD) during the recent three months, expressing a mix of bullish ...
Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ: PODD) with a Buy and raises the price target from $353...
Small-cap and blue-chip stocks advanced in Wednesday morning trading on Wall Street, while technology names lagged and the S&am...
Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump tech...
